NCT00002399已完成2 期
A Multicenter, Randomized, Double-Blind, Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Multiple Doses of SCH 56592 Versus Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients
Schering-Plough80 个研究点 分布在 16 个国家目标入组 500 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 500
- 试验地点
- 80
研究概览
简要总结
The purpose of this study is to compare the safety and effectiveness of SCH 56592 with that of fluconazole in the treatment of OPC (a fungal infection of the throat) in HIV-positive patients.
详细描述
This is a randomized, multicenter, double-blind study consisting of 5 arms (4 dose levels of SCH 56592 vs fluconazole) in the treatment of oropharyngeal candidiasis (OPC) in HIV-positive patients.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •Documented HIV seropositivity (by Western blot or other approved confirmatory test) prior to enrollment.
- •Pseudomembranous oropharyngeal candidiasis.
- •Fungal stain or KOH consistent with Candida species, confirmed by a positive mycologic culture.
- •Ability to swallow study medication.
排除标准
- •Co-existing Condition:
- •Patients with any of the following symptoms and conditions are excluded:
- •Medical condition requiring use of prohibited drugs.
- •Primary HIV seroconversion-related mucosal candidiasis.
- •Systemic candidiasis.
- •All forms of OPC other than pseudomembranous (unless accompanied by pseudomembranous OPC).
- •Documented or suspected fungal esophagitis in patients with symptoms of esophagitis.
- •EKG with prolonged QTc interval or clinically-significant abnormalities.
- •Concurrent Medication:
- •Systemic antifungals (IV or oral).
- •Topical oral antifungals, e.g., Nystatin, Mycelex, etc.
- •Medications known to interact with azoles and that may lead to life-threatening side effects:
- •terfenadine, astemizole, cisapride, ebastine, triazolam, midazolam.
- •Medications known to lower the serum concentration/efficacy of azole antifungals:
- •rifampin, carbamazepine, phenytoin, rifabutin, barbiturates, isoniazid, H2 blockers.
- •Cytokines (except erythropoietin), interferon, or lymphocyte replacement therapy unless patient already taking these agents for at least 30 days prior to enrollment.
- •Protease inhibitors, starting for the first time, 30 days prior to study enrollment.
- •Cytotoxic therapy for cancer.
- •Oral or intravenous corticosteroids at supraphysiologic doses (prednisone 10 mg/day or greater; hydrocortisone 40 mg/day or greater; dexamethasone 2 mg/day or greater.
- •Patients with any of the following prior conditions are excluded:
- •Prior enrollment in this study.
- •Less than 3 months life expectancy.
- •History of hypersensitivity to azole antifungals.
- •History of failed therapy with fluconazole 100 mg/day for 2 weeks in the last 3 months.
- •Prior Medication:
- •Excluded (wash-outs for medications):
- •Systemic antifungals (IV, oral) within 14 days prior to enrollment.
- •Topical oral antifungals within 1 day prior to enrollment.
- •Oral or intravenous corticosteroids at supraphysiologic doses within 10 days prior to enrollment.
- •Astemizole within 10 days prior to enrollment.
- •Drugs known to lower the serum concentration/efficacy of azole antifungals within 30 days prior to enrollment.
- •Investigational drug (unlicensed new chemical entity) use within 30 days prior to enrollment.
- •Current known drug abuse, in the opinion of the lead investigator, that would interfere with the subject's participation in the study.
研究者
研究点 (80)
Loading locations...
相似试验
已完成
2 期
Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic ChemotherapyNausea and Vomiting, Chemotherapy-InducedChemotherapy-Induced Nausea and VomitingNCT00104403GlaxoSmithKline722
终止
2 期
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With PlaceboSchizophreniaNCT00570063Pfizer35
已完成
2 期
Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin TherapyType 2 Diabetes MellitusNCT01240759Shionogi218
撤回
2 期
Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)SchizophreniaNCT00988728Merck Sharp & Dohme LLC
已完成
3 期
A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque PsoriasisPlaque PsoriasisNCT02367911Therapeutics, Inc.144